Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Cochrane Database Syst Rev ; (4): CD005523, 2007 Oct 17.
Article in English | MEDLINE | ID: mdl-17943863

ABSTRACT

BACKGROUND: Clinical experience indicates that aquatic exercise may have advantages for osteoarthritis patients. OBJECTIVES: To compare the effectiveness and safety of aquatic-exercise interventions in the treatment of knee and hip osteoarthritis. SEARCH STRATEGY: We searched MEDLINE from 1949, EMBASE from 1980, CENTRAL (Issue 2, 2006), CINAHL from 1982, Web of Science from 1945, all up to May 2006. There was no language restriction. SELECTION CRITERIA: Randomised controlled trials or quasi-randomised clinical trials. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials for inclusion, assessed the internal validity of included trials and extracted data. Pooled results were analyzed using standardized mean differences (SMD). MAIN RESULTS: There is a lack of high-quality studies in this area. In total, six trials (800 participants) were included. At the end of treatment for combined knee and hip osteoarthritis, there was a small-to-moderate effect on function (SMD 0.26, 95% confidence interval (CI) 0.11 to 0.42) and a small-to-moderate effect on quality of life (SMD 0.32, 95% CI 0.03 to 0.61). A minor effect of a 3% absolute reduction (0.6 fewer points on a 0 to 20 scale) and 6.6% relative reduction from baseline was found for pain. There was no evidence of effect on walking ability or stiffness immediately after end of treatment. No evidence of effect on pain, function or quality of life were observed on the one trial including participants with hip osteoarthritis alone. Only one trial was identified including knee osteoarthritis alone, comparing aquatic exercise with land-based exercise. Immediately after treatment, there was a large effect on pain (SMD 0.86, 95%CI 0.25 to 1.47; 22% relative percent improvement), but no evidence of effect on stiffness or walking ability. Only two studies reported adverse effects, that is, the interventions did not increase self-reported pain or symptom scores. No radiographic evaluation was performed in any of the included studies. AUTHORS' CONCLUSIONS: Aquatic exercise appears to have some beneficial short-term effects for patients with hip and/or knee OA while no long-term effects have been documented. Based on this, one may consider using aquatic exercise as the first part of a longer exercise programme for osteoarthritis patients. The controlled and randomised studies in this area are still too few to give further recommendations on how to apply the therapy, and studies of clearly defined patient groups with long-term outcomes are needed to decide on the further use of this therapy in the treatment of osteoarthritis.


Subject(s)
Exercise Therapy/methods , Osteoarthritis, Hip/therapy , Osteoarthritis, Knee/therapy , Water , Balneology , Chronic Disease , Exercise , Humans , Hydrotherapy/methods , Randomized Controlled Trials as Topic , Swimming
2.
Ugeskr Laeger ; 163(40): 5507-13, 2001 Oct 01.
Article in Danish | MEDLINE | ID: mdl-11601116

ABSTRACT

Aquatic therapy is a subgroup of balneotherapy and consists of exercises in a hot water pool. It uses the physical properties of water to achieve better mobility for patients whose pain, lack of muscle strength, and joint deformities are inhibiting factors when exercising on land. Pool therapy shows positive effects as part of the treatment of rheumatoid arthritis patients, but too few studies with an acceptable design and a well-defined patient group have been carried out. The documentation available on aquatic therapy indicates that more large clinical, controlled, and randomised studies must be conducted.


Subject(s)
Arthritis, Rheumatoid/therapy , Balneology/methods , Exercise Therapy/methods , Hydrotherapy/methods , Controlled Clinical Trials as Topic , Hot Temperature/therapeutic use , Humans , Randomized Controlled Trials as Topic
3.
Int J Cancer ; 75(3): 362-7, 1998 Jan 30.
Article in English | MEDLINE | ID: mdl-9455794

ABSTRACT

Former blue asbestos workers known to be at high risk of asbestos-related diseases, particularly malignant mesothelioma and lung cancer, were enrolled in a chemo-prevention program using vitamin A. Our aims were to compare rates of disease and death in subjects randomly assigned to beta-carotene or retinol. Subjects were assigned randomly to take 30 mg/day beta-carotene (512 subjects) or 25,000 IU/day retinol (512 subjects) and followed up through death and cancer registries from the start of the study in June 1990 till May 1995. Comparison between groups was by Cox regression in both intention-to-treat analyses and efficacy analyses based on treatment actually taken. Median follow-up time was 232 weeks. Four cases of lung cancer and 3 cases of mesothelioma were observed in subjects randomised to retinol and 6 cases of lung cancer and 12 cases of mesothelioma in subjects randomised to beta-carotene. The relative rate of mesothelioma (the most common single cause of death in our study) for those on retinol compared with those on beta-carotene was 0.24 (95% CI 0.07-0.86). In the retinol group, there was also a significantly lower rate for death from all causes but a higher rate of ischaemic heart disease mortality. Similar results were found with efficacy analyses. Our results confirm other findings of a lack of any benefit from administration of large doses of synthetic beta-carotene. The finding of significantly lower rates of mesothelioma among subjects assigned to retinol requires further investigation.


Subject(s)
Anticarcinogenic Agents/therapeutic use , Asbestos, Crocidolite/adverse effects , Lung Neoplasms/prevention & control , Mesothelioma/prevention & control , Occupational Exposure , Vitamin A/therapeutic use , beta Carotene/therapeutic use , Adult , Aged , Aged, 80 and over , Female , Humans , Incidence , Lung Neoplasms/etiology , Lung Neoplasms/mortality , Male , Mesothelioma/etiology , Mesothelioma/mortality , Middle Aged , Myocardial Ischemia/etiology , Myocardial Ischemia/prevention & control , Patient Compliance , Risk Factors , Smoking/adverse effects , Vitamin A/adverse effects , beta Carotene/adverse effects
4.
Plast Reconstr Surg ; 97(6): 1179-93; discussion 1194-5, 1996 May.
Article in English | MEDLINE | ID: mdl-8628800

ABSTRACT

Radiolucent breast implants filled with triglyceride oil have recently entered limited clinical trials. To investigate the questions of oil bleed and the fate of triglycerides that might escape from ruptured breast implants, experiments reported here used peanut oil labeled with radioisotopes so that it could be traced in the urine, feces, and organs of two groups of rabbits. In one experiment, 18 rabbits were implanted with peanut oil-filled implants labeled with tritium to determine whether triglycerides diffuse across silicone elastomer shells. In another experiment, 19 rabbits were injected with 14C-labeled peanut oil to study what might happen to the oil if an implant ruptures. At the end of the follow-up period, we measured radioisotope levels in tissue samples taken from the periprosthetic capsule or injection site of each rabbit, as well as from major organs and the subcutaneous fat on the dorsum opposite the experimental site. One experiment revealed that triglycerides do bleed across the implant shells. Tritium levels were highest in the implant capsule, the omentum, the aorta, and the subcutaneous fat on the nonexperimental side. In the experiment simulating implant rupture, 14C levels were above the background radiation count at the injection site and in the same tissue sites as in the bleed experiment. Both in vivo radiolabeling studies indicate that triglycerides freed from implants by means of bleed or rupture would be absorbed, metabolized, and either excreted or redistributed to the body's normal fat storage sites if they are not needed for energy. In a third in vitro experiment, triglyceride oil specimens were inoculated with various microorganisms associated with wound infections: Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Staphylococcus epidermidis, and diphtheroids. The data demonstrate that neutral triglycerides used as a breast implant filler do not support growth of common infection-producing bacteria and suggest that triglycerides may have bactericidal properties.


Subject(s)
Breast Implants , Triglycerides/chemistry , Triglycerides/pharmacokinetics , Adipose Tissue/metabolism , Animals , Aorta/metabolism , Arachis , Biology , Carbon Radioisotopes , Equipment Design , Equipment Failure , Escherichia coli/growth & development , Feces/chemistry , Female , Follow-Up Studies , Mammary Glands, Animal/metabolism , Omentum , Peanut Oil , Plant Oils/chemistry , Plant Oils/pharmacokinetics , Pseudomonas aeruginosa/growth & development , Rabbits , Silicone Elastomers/chemistry , Staphylococcus aureus/growth & development , Staphylococcus epidermidis/growth & development , Tissue Distribution , Tritium
5.
Tidsskr Nor Laegeforen ; 112(20): 2642-6, 1992 Aug 30.
Article in Norwegian | MEDLINE | ID: mdl-1412289

ABSTRACT

The aim of the investigation was twofold: to study the effect of lovastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, alone and in combination with other lipid lowering drugs in an open 48 week single centre study, and to study if lipid lowering drugs influence adherence to diet in adult patients with familial hypercholesterolemia. Lovastatin monotherapy (80 mg daily) for 12 weeks reduced serum cholesterol, LDL-cholesterol and triglycerides levels by 36%, 44% and 24% respectively. HDL-cholesterol level was increased by 12%. The addition of 16 g cholestyramine daily further increased the reduction of total cholesterol and LDL-cholesterol levels by 17% and 24% respectively. Addition of 1 g probucol daily decreased total cholesterol, LDL-cholesterol and HDL-cholesterol levels by 9%, 5% and 27% respectively. Addition of omega-3-fatty acids (3.6 g daily) reduced total cholesterol, LDL-cholesterol and triglycerides levels by 10%, 12% and 20% respectively. Administration of potent lipid lowering agents did not influence adherence to a diet with a mean daily fat energy of 21% (CI: 20-22), cholesterol of 177 mg (CI: 157-196) and P/S ratio of 0.75 (CI: 0.66-0.84). A significant increase in liver enzymes was recorded in only one patient. One patient was withdrawn from the study because of myositis.


Subject(s)
Hyperlipoproteinemia Type II/drug therapy , Hypolipidemic Agents/therapeutic use , Lovastatin/therapeutic use , Adolescent , Adult , Aged , Cholestyramine Resin/adverse effects , Cholestyramine Resin/therapeutic use , Drug Evaluation , Drug Therapy, Combination , Humans , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/diet therapy , Hypolipidemic Agents/adverse effects , Lovastatin/adverse effects , Middle Aged
6.
Plast Reconstr Surg ; 88(3): 462-74, 1991 Sep.
Article in English | MEDLINE | ID: mdl-1871225

ABSTRACT

Current implants for breast augmentation containing silicone gel, saline, or both are radiopaque on mammographic examination and can totally obscure microcalcifications and soft-tissue masses. The effect of these implants on the detection of early breast cancers in patients who have undergone augmentation mammaplasty remains unproven and controversial. Implants filled with medium-chain triglycerides (peanut oil) are radiolucent on mammographic examination and allow visualization of both soft-tissue masses and microcalcifications. To investigate the biocompatibility of radiolucent implants, 10 cc of sterile, nonpyrogenic peanut oil was injected subcutaneously into rats using silicone gel as a control. Twenty-one rabbits had two 125-cc silicone shell implants inserted on either side of the chest wall. The right-sided shell was filled with 125 cc of sterile saline, and the left-sided shell was filled with 125 cc of sterile, nonpyrogenic peanut oil. Results were determined by both histologic and radiographic examination. Rats injected with peanut oil equivalent to 7 percent of their body weight rapidly absorbed the freely injected oil without detriment. Histologic examination of the lungs, liver, kidneys, and tissues adjacent to the injection sites demonstrated no abnormalities. There was no evidence of allergic, toxic, inflammatory, or neoplastic response. Eighteen of 21 rabbits survived more than 3 months. Radiographs showed the oil-filled implants to be radiolucent, whereas the saline-filled controls obscured the surrounding soft and bony tissues. Histologic examination demonstrated a fibrous capsule surrounding both types of implants. Histologic examination of the lungs, liver, and kidneys showed no significant abnormalities. These and previous studies have shown peanut oil to be biocompatible when freely injected either intramuscularly or subcutaneously. This study demonstrates that a radiolucent, peanut oil-filled implant is biocompatible in animals and that further long-term studies for its use in humans are merited.


Subject(s)
Biocompatible Materials , Mammography , Plant Oils/toxicity , Prostheses and Implants , Animals , Arachis , Breast Neoplasms/diagnosis , Female , Gels , Humans , Isotonic Solutions , Materials Testing , Peanut Oil , Rabbits , Rats , Rats, Inbred Strains , Silicones , Sodium Chloride
7.
Arterioscler Thromb ; 11(1): 138-45, 1991.
Article in English | MEDLINE | ID: mdl-1987991

ABSTRACT

The present study was performed to determine the influence of pharmaceutical intervention on parameters of blood coagulation and fibrinolysis in hypercholesterolemic patients. Eighteen otherwise-healthy individuals with heterozygous familial hypercholesterolemia were treated with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (simvastatin, 40 mg daily) for 12-14 weeks followed by additional treatment with omega-3 fatty acids (equivalent to 4 g eicosapentaenoic acid/docosahexaenoic acid daily) for 6 more weeks. With simvastatin treatment, the mean decreases in total cholesterol, low density lipoprotein (LDL) cholesterol, and apolipoprotein B (apo B) were 39%, 46%, and 36%, respectively. Only minor changes in high density lipoprotein (HDL) cholesterol and apo A-1 were recorded. omega-3 fatty acids had minor additional effects. The most prominent effects on the blood coagulation system were the changes in extrinsic pathway inhibitor (EPI), which is the inhibitor of the factor VIIa-tissue thromboplastin complex. EPI activity decreased from a median of 153% to 111% (p less than 0.001) with simvastatin treatment and to 112% (p less than 0.001) on the combined regimen. EPI activity was significantly correlated with LDL cholesterol (r = 0.78), total cholesterol (r = 0.77), apo B (r = 0.65), and apo A-1 (r = 0.45). Multiple stepwise regression analysis showed that LDL cholesterol was the most important predictor of EPI activity, which suggests that a majority of EPI activity in plasma is associated with LDL. Moreover, the alteration in EPI activity was correlated closely with the corresponding alteration in LDL, which suggests a direct relation between a coagulation-inhibitor activity and a pharmaceutical lipid-related response.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Anticholesteremic Agents/therapeutic use , Blood Coagulation/drug effects , Hyperlipoproteinemia Type II/drug therapy , Lovastatin/analogs & derivatives , Adult , Apolipoproteins A/blood , Apolipoproteins B/blood , Blood Coagulation/physiology , Cholesterol/blood , Cholesterol, HDL/blood , Cholesterol, LDL/blood , Factor VII/drug effects , Factor VII/physiology , Humans , Hyperlipoproteinemia Type II/physiopathology , Lovastatin/therapeutic use , Male , Middle Aged , Simvastatin
SELECTION OF CITATIONS
SEARCH DETAIL